Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening

被引:39
|
作者
Menon, U
Talaat, A
Rosenthal, AN
Macdonald, ND
Jeyerajah, AR
Skates, SJ
Sibley, K
Oram, DH
Jacobs, IJ [1 ]
机构
[1] St Bartholomews Hosp, Royal Hosp NHS Trust, Gynaecol Canc Res Unit, London EC1A 7BE, England
[2] Harvard Univ, Sch Med, Dept Med, Boston, MA USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源
基金
英国医学研究理事会;
关键词
D O I
10.1111/j.1471-0528.2000.tb11685.x
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective To assess the performance of ultrasonography in a multimodal ovarian cancer screening strategy. Design Prospective ovarian cancer screening trial between December 1986 and June 1993. Setting General practice, occupational health departments and an ovarian cancer screening clinic at a London teaching hospital. Population Postmenopausal women, greater than or equal to 45 years with a raised CA125. Methods Volunteers with a CA125 greater than or equal to 30 U/mL underwent a pelvic ultrasound. Scans were classified as normal, abnormal (ovarian volume greater than or equal to 8.8 mL) or equivocal (normal volume with abnormal morphology). Abnormal ovarian morphology was subclassified as simple cyst (single, thin walled cyst with no septa or papillary projections) or complex (all other abnormalities). Volunteers with abnormal scans were referred for a gynaecological opinion. Follow up was via the cancer registry and postal questionnaires. Main outcome measures Sensitivity, specificity and positive predictive value of different ultrasound criteria for detection of index cancer (e.g. primary invasive epithelial carcinoma of the ovary and fallopian tube). Results Seven hundred and forty-one women underwent 1219 scans and 20 index cancers occurred during a median follow up of 6.8 years. The sensitivity for detection of ovarian cancer of different ultrasound criteria was 100% for abnormal morphology, 89.5% for abnormal volume and 84% for complex morphology. The highest specificity (97%) and positive predictive value (37.2%) was achieved using complex morphology. Conclusion A variety of ultrasound criteria can achieve high sensitivity, specificity and positive predictive value for index cancers in postmenopausal women with an elevated CA125. Use of ovarian morphology to interpret ultrasound may increase sensitivity and use of complex ovarian morphology may increase the positive predictive value.
引用
收藏
页码:165 / 169
页数:5
相关论文
共 50 条
  • [1] Commentary on 'Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening'
    Wan, Y. L.
    Crosbie, E. J.
    [J]. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2014, 121 : 40 - 47
  • [2] Performance of ultrasound as a second line test to serum CA 125 in ovarian cancer screening
    Menon, Usha
    Talaat, Ahmed
    Rosenthal, Adam N.
    Macdonald, Nicola D.
    Jeyerajah, Arjun R.
    Skates, Steven J.
    Sibley, Karen
    Oram, David H.
    Jacobs, Ian J.
    [J]. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2014, 121 : 35 - 39
  • [3] Personalizing CA125 Levels for Ovarian Cancer Screening
    Dorigo, Oliver
    Berek, Jonathan S.
    [J]. CANCER PREVENTION RESEARCH, 2011, 4 (09) : 1356 - 1359
  • [4] CA125 in ovarian cancer
    Scholler, Nathalie
    Urban, Nicole
    [J]. BIOMARKERS IN MEDICINE, 2007, 1 (04) : 513 - 523
  • [5] Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: A prospective cohort study
    Bosse, Kristin
    Rhiem, Kerstin
    Wappenschmidt, Barbara
    Hellmich, Martin
    Madeja, Martin
    Ortmann, Monika
    Mallmann, Peter
    Schmutzler, Rita
    [J]. GYNECOLOGIC ONCOLOGY, 2006, 103 (03) : 1077 - 1082
  • [6] CA125 expression at clinical diagnosis by ovarian carcinoma not detected through antecedent serum CA125 screening
    Woolas, RP
    Oram, DH
    PrysDavies, A
    Leake, J
    Brown, CL
    Jacobs, IJ
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1996, 6 (02) : 98 - 101
  • [7] Serum CA125 level before the development of ovarian cancer
    Kobayashi, H.
    Ooi, H.
    Yamada, Y.
    Sakata, M.
    Kawaguchi, R.
    Kanayama, S.
    Sumimoto, K.
    Terao, T.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2007, 99 (02) : 95 - 99
  • [8] SERUM CA125 LEVEL BEFORE THE DEVELOPMENT OF OVARIAN CANCER
    Kobayashi, H.
    Ooi, H.
    Yamada, Y.
    Sakata, M.
    Kawaguchi, R.
    Kanayama, S.
    Sumimoto, K.
    Terao, T.
    [J]. GIORNALE ITALIANO DI OSTETRICIA E GINECOLOGIA, 2008, 30 (03): : 91 - 96
  • [9] CA125 GLYCOFORM ASSAY IMPROVES THE PERFORMANCE OF CONVENTIONAL CA125 IN THE DIAGNOSTICS OF EPITHELIAL OVARIAN CANCER
    Salminen, L.
    Gidwani, K.
    Rolfsen, A. L.
    Nadeem, N.
    Bolstad, N.
    Dorum, A.
    Grenman, S.
    Hietanen, S.
    Perheentupa, A.
    Poutanen, M.
    Carpen, O.
    Lamminmaki, U.
    Pettersson, K.
    Hynninen, J.
    Huhtinen, K.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 825 - 825
  • [10] COMBINATION OF IMMUNOSCINTIGRAPHY AND CA125 SERUM LEVELS IN OVARIAN-CANCER
    SCHATTEN, C
    PATEISKEY, N
    SEVELDA, P
    CZERWENKA, K
    BARRADA, M
    PHILIPP, K
    BURCHELL, J
    [J]. BRITISH JOURNAL OF CANCER, 1989, 59 (02) : 322 - 322